162 related articles for article (PubMed ID: 34591931)
1. Analysis of acute lymphoblastic leukemia drug sensitivity by changes in impedance via stromal cell adherence.
Luong A; Cerignoli F; Abassi Y; Heisterkamp N; Abdel-Azim H
PLoS One; 2021; 16(9):e0258140. PubMed ID: 34591931
[TBL] [Abstract][Full Text] [Related]
2. Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia.
Tarighat SS; Fei F; Joo EJ; Abdel-Azim H; Yang L; Geng H; Bum-Erdene K; Grice ID; von Itzstein M; Blanchard H; Heisterkamp N
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830047
[TBL] [Abstract][Full Text] [Related]
3. Close interaction with bone marrow mesenchymal stromal cells induces the development of cancer stem cell-like immunophenotype in B cell precursor acute lymphoblastic leukemia cells.
Kihira K; Chelakkot VS; Kainuma H; Okumura Y; Tsuboya N; Okamura S; Kurihara K; Iwamoto S; Komada Y; Hori H
Int J Hematol; 2020 Dec; 112(6):795-806. PubMed ID: 32862292
[TBL] [Abstract][Full Text] [Related]
4. Galectin-1 and Galectin-3 in B-Cell Precursor Acute Lymphoblastic Leukemia.
Fei F; Zhang M; Tarighat SS; Joo EJ; Yang L; Heisterkamp N
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430839
[TBL] [Abstract][Full Text] [Related]
5. Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia.
George AA; Paz H; Fei F; Kirzner J; Kim YM; Heisterkamp N; Abdel-Azim H
PLoS One; 2015; 10(9):e0137917. PubMed ID: 26360058
[TBL] [Abstract][Full Text] [Related]
6. Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008.
Paz H; Joo EJ; Chou CH; Fei F; Mayo KH; Abdel-Azim H; Ghazarian H; Groffen J; Heisterkamp N
J Exp Clin Cancer Res; 2018 Mar; 37(1):67. PubMed ID: 29580262
[TBL] [Abstract][Full Text] [Related]
7. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.
Bertamini L; Nanni J; Marconi G; Abbenante M; Robustelli V; Bacci F; Matti A; Paolini S; Sartor C; Monaco SL; Fontana MC; De Polo S; Cavo M; Curti A; Martinelli G; Papayannidis C
BMC Cancer; 2018 Nov; 18(1):1117. PubMed ID: 30442119
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells.
Iwasa M; Miura Y; Fujishiro A; Fujii S; Sugino N; Yoshioka S; Yokota A; Hishita T; Hirai H; Andoh A; Ichinohe T; Maekawa T
Int J Hematol; 2017 May; 105(5):587-597. PubMed ID: 28044259
[TBL] [Abstract][Full Text] [Related]
9. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia.
Cayuela JM; Baruchel A; Orange C; Madani A; Auclerc MF; Daniel MT; Schaison G; Sigaux F
Blood; 1996 Jul; 88(1):302-8. PubMed ID: 8704188
[TBL] [Abstract][Full Text] [Related]
10. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
[TBL] [Abstract][Full Text] [Related]
11. Multi-Faceted Effects of ST6Gal1 Expression on Precursor B-Lineage Acute Lymphoblastic Leukemia.
Zhang M; Qi T; Yang L; Kolarich D; Heisterkamp N
Front Oncol; 2022; 12():828041. PubMed ID: 35371997
[TBL] [Abstract][Full Text] [Related]
12. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).
Fei F; Lim M; Schmidhuber S; Moll J; Groffen J; Heisterkamp N
Mol Cancer; 2012 Jun; 11():42. PubMed ID: 22721004
[TBL] [Abstract][Full Text] [Related]
13. Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia.
Jakobczyk H; Debaize L; Soubise B; Avner S; Rouger-Gaudichon J; Commet S; Jiang Y; Sérandour AA; Rio AG; Carroll JS; Wichmann C; Lie-A-Ling M; Lacaud G; Corcos L; Salbert G; Galibert MD; Gandemer V; Troadec MB
J Hematol Oncol; 2021 Mar; 14(1):47. PubMed ID: 33743795
[TBL] [Abstract][Full Text] [Related]
14. Understanding the reconstitution of the B-cell compartment in bone marrow and blood after treatment for B-cell precursor acute lymphoblastic leukaemia.
Theunissen PMJ; van den Branden A; Van Der Sluijs-Gelling A; De Haas V; Beishuizen A; van Dongen JJM; Van Der Velden VHJ
Br J Haematol; 2017 Jul; 178(2):267-278. PubMed ID: 28542787
[TBL] [Abstract][Full Text] [Related]
15. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro.
Juarez J; Bradstock KF; Gottlieb DJ; Bendall LJ
Leukemia; 2003 Jul; 17(7):1294-300. PubMed ID: 12835717
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
Frismantas V; Dobay MP; Rinaldi A; Tchinda J; Dunn SH; Kunz J; Richter-Pechanska P; Marovca B; Pail O; Jenni S; Diaz-Flores E; Chang BH; Brown TJ; Collins RH; Uhrig S; Balasubramanian GP; Bandapalli OR; Higi S; Eugster S; Voegeli P; Delorenzi M; Cario G; Loh ML; Schrappe M; Stanulla M; Kulozik AE; Muckenthaler MU; Saha V; Irving JA; Meisel R; Radimerski T; Von Stackelberg A; Eckert C; Tyner JW; Horvath P; Bornhauser BC; Bourquin JP
Blood; 2017 Mar; 129(11):e26-e37. PubMed ID: 28122742
[TBL] [Abstract][Full Text] [Related]
17. Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy.
Tesfai Y; Ford J; Carter KW; Firth MJ; O'Leary RA; Gottardo NG; Cole C; Kees UR
Leuk Res; 2012 Mar; 36(3):299-306. PubMed ID: 21889797
[TBL] [Abstract][Full Text] [Related]
18. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
19. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
20. Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia.
Fidyt K; Pastorczak A; Goral A; Szczygiel K; Fendler W; Muchowicz A; Bartlomiejczyk MA; Madzio J; Cyran J; Graczyk-Jarzynka A; Jansen E; Patkowska E; Lech-Maranda E; Pal D; Blair H; Burdzinska A; Pedzisz P; Glodkowska-Mrowka E; Demkow U; Gawle-Krawczyk K; Matysiak M; Winiarska M; Juszczynski P; Mlynarski W; Heidenreich O; Golab J; Firczuk M
Mol Oncol; 2019 May; 13(5):1180-1195. PubMed ID: 30861284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
